A Prospective Study of Surgical Treatment Strategies for Chordoma

Surgery Clinical Trial

Official title:

A Prospective Study of Surgical Treatment Strategies for Chordoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05707767
• Other study ID #: XW-NS-CHORC
• Status: Recruiting
• Phase: N/A
• Start date: February 1, 2023
• Est. completion date: September 30, 2024

Study information

• Verified date: October 2022
• Source: Xuanwu Hospital, Beijing
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chordoma is a rare but locally invasive cancer that arises from the embryonic notochord. Total resection is challenging in mobile spine because of the complex anatomy and bone invasion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 30, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Between the ages of 18 and 70 ys,

• With a diagnosis of chordoma confirmed by pathology,

• Undergone surgical treatment in our hospital,

• Available for clinical follow-up and agree to long-term clinical follow-up and sign informed consent.

Exclusion Criteria:

• Suffer from other tumors,

• Suffer from cardiovascular disease, cerebrovascular disease, or immune system disease.

Related Conditions & MeSH terms

• Chordoma
• Chordoma of Spine
• Surgery

Intervention

Procedure:
• Resection surgery
Patients undergo resection surgery in our hospital.

Locations

Country	Name	City	State
China	Xuanwu Hospital, Capital Medical University	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

References & Publications (5)

Kolz JM, Wellings EP, Houdek MT, Clarke MJ, Yaszemski MJ, Rose PS. Surgical treatment of primary mobile spine chordoma. J Surg Oncol. 2021 Apr;123(5):1284-1291. doi: 10.1002/jso.26423. Epub 2021 Feb 10. — View Citation

Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012 Feb;13(2):e69-76. doi: 10.1016/S1470-2045(11)70337-0. — View Citation

Wedekind MF, Widemann BC, Cote G. Chordoma: Current status, problems, and future directions. Curr Probl Cancer. 2021 Aug;45(4):100771. doi: 10.1016/j.currproblcancer.2021.100771. Epub 2021 Jul 1. — View Citation

Williams BJ, Raper DM, Godbout E, Bourne TD, Prevedello DM, Kassam AB, Park DM. Diagnosis and treatment of chordoma. J Natl Compr Canc Netw. 2013 Jun 1;11(6):726-31. doi: 10.6004/jnccn.2013.0089. — View Citation

Yeter HG, Kosemehmetoglu K, Soylemezoglu F. Poorly differentiated chordoma: review of 53 cases. APMIS. 2019 Sep;127(9):607-615. doi: 10.1111/apm.12978. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Excision Extension	Clinical and radiographic assessments of excision extension of tumor.	1 week after surgery.
Secondary	OS (Overall Survival)	Overall Survival of patient underwent surgery.	2 years
Secondary	PFS (Progression-Free Survival)	Progression-Free Survival of patient underwent surgery.	2 years
Secondary	DFS (Disease Free Survival)	Disease Free Survival of patient underwent surgery.	2 years
Secondary	ORR (Objective Response Rate)	Objective Response Rate of patient underwent surgery.	2 years